56.7007.05% ( -4.300 )
Delay Closed: Nov 20, 16:08:12Valuation
Current ValuationThe current P/E ratio is -47.92, within the reasonable range, cheaper than 55.33% of the time in the past 5 years, and the industry ranks 71/78, the industry Median -4.43.
-47.92xP/E
HK$56.70Stock price
HK$-1.18Earnings per share
-47.92xP/E
Stock priceHK$56.70Earnings per shareHK$-1.18
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -25.82x
- Typical range
- -102.97x–15.07x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0137274411548
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
09926HKAKESO | -47.92x | 66.53% | HK$53.36B |
09688HKZAI LAB | -13.25x | 11.94% | HK$20.62B |
01877HKJUNSHI BIO | -29.50x | 83.59% | HK$13.55B |
02627HKAB&B BIO-TECH-B | -46.87x | -- | HK$11.54B |
02616HKCSTONE PHARMA-B | -18.80x | 1.09% | HK$9.07B |
06855HKASCENTAGE | -5.18x | 19.15% | HK$8.76B |
07666HKMETIS TECHBIO-P | -19.31x | 96.67% | HK$7.86B |
09606HKDUALITYBIO-B | -4.69x | 85.35% | HK$7.78B |
01952HKEVEREST MED | -124.31x | 284.92% | HK$7.72B |
02493HKMABWELL-B | -6.22x | -- | HK$7.61B |
06938HKRIBOLIFE-B | -35.05x | 29.56% | HK$6.85B |
02595HKGENFLEET-B | -4.43x | 66.07% | HK$6.72B |
02335HKMICOT PHARMA-B | -14.55x | 37.52% | HK$6.10B |
09887HKLEADS BIOLABS-B | -18.25x | 3.57% | HK$5.61B |
02171HKCARSGEN-B | -53.82x | 52.33% | HK$5.53B |
09966HKALPHAMAB-B | -24.32x | -- | HK$4.93B |
00775HKCKLIFE SCIENCES | -72.79x | -- | HK$4.71B |
01672HKASCLETIS-B | -6.61x | 78.53% | HK$4.50B |
02256HKABBISKO-B | -7.57x | 814.43% | HK$4.07B |
06872HKTENNOR THERAP-B | -23.90x | -- | HK$3.83B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
